
**Global Conference on Medical and Health Sciences**
Hosted Online from Madrid, Spain
Date: 14th April, 2026
Website: https://econferencia.com

# INTEGRATION OF RADIOMICS AND MACHINE LEARNING FOR PREDICTING GLIOMA PROGRESSION: A MULTIMODAL IMAGING AND COMPUTATIONAL APPROACH TO PRECISION NEURO-ONCOLOGY

Amirqulov Rahmatilla
Arziqulov Fazliddin
Xayrullayev Islomjon
Tashkent State Medical University, Tashkent, Uzbekistan

**Abstract**

Gliomas represent one of the most aggressive and heterogeneous groups of primary brain tumors, characterized by unpredictable progression patterns and variable clinical outcomes. Accurate prediction of glioma progression remains a major challenge in neuro-oncology, limiting the effectiveness of personalized treatment strategies. Traditional diagnostic approaches, based on conventional imaging and histopathological evaluation, often fail to capture the complex spatial and temporal heterogeneity of tumor biology.

Radiomics, which involves the extraction of high-dimensional quantitative features from medical imaging, has emerged as a powerful tool for characterizing tumor phenotype beyond visual assessment. When combined with machine learning algorithms, radiomic features can be used to develop predictive models capable of identifying patterns associated with tumor progression. This integration enables the transformation of imaging data into clinically actionable information, supporting precision medicine in neuro-oncology.

This study explores the role of radiomics and machine learning in predicting glioma progression through the analysis of multimodal imaging data, including MRI-based structural and functional parameters. Advanced machine learning

models, including random forests, support vector machines, and deep learning architectures, were evaluated for their ability to integrate radiomic features and predict disease progression.

The results indicate that radiomics-based models significantly improve predictive accuracy compared to conventional imaging assessment. The integration of machine learning enhances the ability to identify subtle imaging patterns associated with tumor growth, infiltration, and treatment response. These models demonstrate strong potential for early detection of progression, risk stratification, and individualized treatment planning.

However, challenges remain, including variability in imaging protocols, feature reproducibility, and the need for large, standardized datasets. Additionally, model interpretability and clinical integration require further development.

In conclusion, the integration of radiomics and machine learning represents a promising approach for improving the prediction of glioma progression, supporting data-driven decision-making and advancing precision neuro-oncology.

**Keywords:** Radiomics; Glioma progression; Machine learning; Neuro-oncology; MRI; Predictive modeling; Tumor heterogeneity; Precision medicine; Artificial intelligence; Medical imaging

## Introduction

Gliomas are among the most prevalent and aggressive primary brain tumors, accounting for a significant proportion of central nervous system malignancies. These tumors exhibit marked biological heterogeneity, variable growth dynamics, and diverse clinical outcomes, ranging from relatively indolent low-grade gliomas to highly aggressive glioblastomas. Despite advances in surgical

techniques, radiotherapy, and chemotherapy, the prognosis of high-grade gliomas remains poor, largely due to their infiltrative nature and resistance to treatment. One of the major challenges in neuro-oncology is the accurate prediction of glioma progression, which is essential for optimizing treatment strategies and improving patient outcomes.

Traditional approaches to assessing glioma progression rely on a combination of clinical evaluation, histopathological grading, and conventional imaging techniques, particularly magnetic resonance imaging (MRI). While MRI provides valuable anatomical and functional information, its interpretation is often limited by subjectivity and an inability to capture the full complexity of tumor heterogeneity. Furthermore, standard imaging criteria, such as changes in tumor size or contrast enhancement, may not accurately reflect underlying biological processes, particularly in the context of treatment-related changes such as pseudoprogression or radiation necrosis.

In recent years, the field of radiomics has emerged as a promising approach to overcoming these limitations. Radiomics involves the extraction of a large number of quantitative features from medical images, including intensity, texture, shape, and spatial relationships. These features provide a detailed representation of tumor phenotype that extends beyond visual assessment, enabling the characterization of intratumoral heterogeneity and microenvironmental changes. By converting imaging data into high-dimensional quantitative information, radiomics facilitates a more objective and reproducible analysis of tumor characteristics.

The integration of radiomics with machine learning represents a significant advancement in predictive modeling for glioma progression. Machine learning algorithms are capable of analyzing complex and high-dimensional datasets, identifying patterns and relationships that are not readily apparent through

conventional analysis. Models such as support vector machines, random forests, and deep neural networks have demonstrated strong performance in classification, regression, and survival prediction tasks in neuro-oncology. When applied to radiomic data, these algorithms enable the development of predictive models that can estimate the likelihood of tumor progression, treatment response, and patient survival.

A key advantage of combining radiomics with machine learning is the ability to incorporate multimodal imaging data. Advanced MRI techniques, including diffusion-weighted imaging (DWI), perfusion imaging, and functional MRI, provide complementary information regarding tumor cellularity, vascularity, and functional connectivity. The integration of these modalities enhances the ability of predictive models to capture the complex biological behavior of gliomas. This multimodal approach aligns with the principles of precision medicine, where treatment decisions are guided by detailed, patient-specific data.

Another important aspect of this integration is its potential to support clinical decision-making. Predictive models based on radiomics and machine learning can provide objective risk assessments, enabling clinicians to stratify patients according to their likelihood of disease progression. This information can be used to guide treatment planning, including decisions regarding surgical resection, adjuvant therapy, and follow-up strategies. Moreover, early prediction of progression may allow for timely intervention, potentially improving patient outcomes.

Despite these promising developments, several challenges remain in the application of radiomics and machine learning in clinical practice. One of the primary limitations is the lack of standardization in imaging acquisition and feature extraction, which can affect the reproducibility and generalizability of radiomic features. Variability in MRI protocols across institutions introduces

heterogeneity that can impact model performance. Additionally, the high dimensionality of radiomic data increases the risk of overfitting, particularly in studies with limited sample sizes.

Another critical challenge is the interpretability of machine learning models. While complex models may achieve high predictive accuracy, their lack of transparency can limit clinical acceptance. Clinicians require models that not only provide accurate predictions but also offer insights into the underlying factors influencing those predictions. The development of explainable AI techniques is therefore essential for bridging the gap between computational modeling and clinical application.

Furthermore, the integration of these technologies into routine clinical workflows requires careful consideration of practical and ethical factors. Issues related to data privacy, algorithmic bias, and regulatory approval must be addressed to ensure the safe and responsible use of AI-driven systems. Interdisciplinary collaboration between clinicians, data scientists, and engineers is essential for developing robust and clinically relevant solutions.

Given these challenges and opportunities, there is a growing need for comprehensive evaluation of the integration of radiomics and machine learning in predicting glioma progression. Understanding how these approaches can improve predictive accuracy and support clinical decision-making is critical for advancing neuro-oncology and achieving the goals of precision medicine.

In this context, the present study aims to investigate the role of radiomics and machine learning in predicting glioma progression, with a focus on enhancing predictive performance, improving risk stratification, and facilitating data-driven clinical decision-making.




## Materials and Methods

This study was designed as a comprehensive analytical and integrative investigation aimed at evaluating the effectiveness of radiomics combined with machine learning in predicting glioma progression. The methodological framework integrates systematic literature analysis, comparative evaluation of computational models, and translational interpretation of clinical applicability, ensuring both scientific rigor and relevance to precision neuro-oncology.

A structured literature search was conducted across major scientific databases, including PubMed, Scopus, and Web of Science, covering publications from 2018 to 2025. The search strategy incorporated a combination of controlled vocabulary and free-text terms such as “radiomics,” “glioma progression,” “machine learning,” “MRI,” “neuro-oncology,” and “predictive modeling.” Boolean operators (AND, OR) were used to refine the search and ensure comprehensive coverage of relevant studies.

Following the initial search, a multi-stage screening process was implemented. Titles and abstracts were first reviewed to exclude irrelevant studies, followed by full-text assessment based on predefined inclusion and exclusion criteria. Studies were included if they (i) applied radiomics and machine learning techniques to glioma imaging data, (ii) reported quantitative performance metrics such as accuracy, sensitivity, specificity, or area under the curve (AUC), and (iii) provided sufficient methodological detail for reproducibility. Studies lacking validation, focusing solely on theoretical model development, or published prior to 2018 were excluded.

Data extraction was performed using a standardized framework to ensure consistency across studies. Extracted variables included imaging modality (e.g., T1-weighted MRI, T2-weighted MRI, FLAIR, diffusion-weighted imaging, perfusion imaging), radiomic feature categories (first-order statistics, texture

features, shape descriptors), machine learning model type (e.g., support vector machines, random forests, gradient boosting, deep neural networks), and clinical endpoints (tumor progression, progression-free survival, treatment response).

Radiomic feature extraction was analyzed as a multi-step process, including image acquisition, preprocessing, segmentation, feature extraction, and feature selection. Image preprocessing techniques such as normalization, resampling, and noise reduction were evaluated for their impact on feature reproducibility. Tumor segmentation methods, including manual, semi-automated, and fully automated approaches, were compared in terms of accuracy and consistency.

Feature selection and dimensionality reduction techniques were critically assessed to address the high dimensionality of radiomic data. Methods such as principal component analysis (PCA), recursive feature elimination, and regularization techniques (e.g., LASSO) were commonly employed to identify the most informative features and reduce the risk of overfitting.

Machine learning models were categorized based on their learning paradigms. Classical machine learning models, including support vector machines and random forests, were compared with deep learning approaches such as convolutional neural networks (CNNs). Special attention was given to hybrid models that integrate radiomic features with clinical variables, as these models provide a more comprehensive representation of disease progression.

The primary outcome of interest was the predictive performance of models in identifying glioma progression, evaluated using standard metrics such as accuracy, sensitivity, specificity, and AUC. Secondary outcomes included model robustness, generalizability, and clinical applicability. Comparative analysis was performed to assess differences in performance across model types and data integration strategies.




Data synthesis was conducted using both quantitative and qualitative analytical approaches. Quantitative results were summarized to identify trends in model performance, while qualitative analysis focused on interpretability, feature relevance, and clinical integration. Cross-study comparisons were used to identify consistent patterns and potential sources of variability.

Potential sources of bias were critically evaluated, including variability in imaging protocols, dataset imbalance, and lack of external validation. Studies employing cross-validation, independent test sets, or multi-center datasets were considered more reliable and were given greater weight in the analysis.

Furthermore, the translational potential of radiomics-based models was assessed by evaluating their integration into clinical workflows. Factors such as computational efficiency, reproducibility of radiomic features, and compatibility with existing imaging systems were considered. Studies reporting clinician involvement or real-world implementation scenarios were prioritized.

Ethical considerations were also addressed in the selection and interpretation of studies. All included research adhered to established ethical standards, including data privacy regulations and informed consent. Broader ethical issues related to AI in healthcare, such as algorithmic bias and equitable access, were also considered.

Overall, this methodological approach provides a robust and systematic foundation for evaluating the integration of radiomics and machine learning in predicting glioma progression, enabling a comprehensive assessment of both technical performance and clinical relevance.

## Results

The comprehensive analysis demonstrates that the integration of radiomics and machine learning significantly improves the prediction of glioma progression compared to conventional imaging-based assessment. Across multiple studies,

predictive models utilizing radiomic features extracted from multimodal MRI data consistently outperform traditional diagnostic approaches in identifying early tumor progression, treatment response, and disease recurrence.

A key finding is the ability of radiomics to capture intratumoral heterogeneity through quantitative imaging features. These features, including texture, intensity distribution, and shape descriptors, provide detailed information about tumor microstructure and biological behavior. When combined with machine learning algorithms, these features enable the identification of complex patterns associated with tumor growth and progression.

**Graph 1: Predictive Accuracy of Radiomics-Based Models vs Conventional Imaging**






The graph clearly demonstrates that radiomics-based models achieve significantly higher predictive accuracy and AUC values compared to conventional imaging interpretation. Traditional approaches rely on visual assessment of tumor size and contrast enhancement, which often fail to reflect underlying biological processes such as cellular proliferation and infiltration.

Radiomics, by contrast, quantifies subtle imaging patterns that are not visible to the human eye. For example, texture features can capture variations in tumor heterogeneity, while intensity-based features reflect differences in tissue composition. These quantitative measures provide a more comprehensive characterization of tumor behavior.

The improvement in predictive performance is particularly evident in early-stage progression detection, where conventional methods often show limited sensitivity. This highlights the potential of radiomics to enable earlier and more accurate clinical decision-making. Another important finding is the superior performance of multimodal imaging integration, particularly when combining structural and functional MRI data.


**Global Conference on Medical and Health Sciences**
Hosted Online from Madrid, Spain
Date: 14th April, 2026
Website: https://econferencia.com

**Graph 2: Multimodal MRI vs Single-Modality Radiomics Performance**






The graph shows that models incorporating multimodal MRI data significantly outperform those based on a single imaging modality. Structural MRI sequences (T1, T2, FLAIR) provide anatomical information, while advanced techniques such as diffusion-weighted imaging (DWI) and perfusion imaging offer insights into tumor cellularity and vascularity.

The integration of these modalities allows machine learning models to capture multiple aspects of tumor biology simultaneously. For instance, diffusion imaging reflects cellular density, while perfusion imaging provides information about blood flow and angiogenesis. These complementary data sources enhance the model's ability to predict progression.

The results indicate that multimodal integration is essential for achieving high predictive performance, reinforcing the concept that glioma progression is a multifactorial process requiring comprehensive data analysis.

A critical result is the effectiveness of feature selection and dimensionality reduction techniques in improving model performance.

**Graph 3: Impact of Feature Selection on Model Performance**




## Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14th April, 2026

Website: https://econferencia.com




The graph illustrates that the application of feature selection and dimensionality reduction techniques significantly improves model accuracy and generalizability. Radiomic datasets are typically high-dimensional, containing hundreds or thousands of features, many of which may be redundant or irrelevant.

Without proper feature selection, models are prone to overfitting, particularly in studies with limited sample sizes. Techniques such as principal component analysis (PCA) and LASSO regression help identify the most informative features while reducing noise and redundancy.

The improvement in performance observed after feature selection highlights the importance of optimizing input data before model training. This step is critical for ensuring that models remain robust and clinically applicable.

Another significant finding is the comparative performance of machine learning vs deep learning models in radiomics-based prediction.

**Graph 4: Machine Learning vs Deep Learning Performance in Radiomics**




The graph indicates that both classical machine learning models and deep learning approaches achieve strong predictive performance, with deep learning models showing a slight advantage in handling complex imaging data.

Convolutional neural networks (CNNs), in particular, excel in extracting spatial features directly from imaging data without the need for manual feature engineering.

However, classical machine learning models, such as random forests and support vector machines, remain competitive, especially when combined with well-selected radiomic features. These models often require less computational power and may offer greater interpretability, making them more suitable for certain clinical applications.

The results suggest that the choice of model should be guided by the specific clinical context, data availability, and computational resources.

In addition to these findings, the analysis revealed that radiomics-based models demonstrate strong potential in predicting treatment response and disease recurrence, enabling more proactive clinical management. Early identification of progression allows clinicians to adjust treatment strategies, potentially improving patient outcomes.

However, several limitations were identified. Variability in imaging protocols across institutions affects feature reproducibility, while small sample sizes limit model generalizability. The lack of standardized radiomics pipelines remains a significant barrier to clinical adoption.

Overall, the results confirm that the integration of radiomics and machine learning represents a powerful approach for predicting glioma progression, offering improved accuracy, enhanced understanding of tumor biology, and significant potential for clinical application.

## Discussion

The findings of this study provide strong evidence that the integration of radiomics and machine learning represents a significant advancement in the

prediction of glioma progression. By transforming conventional imaging data into high-dimensional quantitative features, radiomics enables a more comprehensive characterization of tumor heterogeneity, which is a key determinant of glioma behavior and clinical outcome. When combined with machine learning algorithms, these features can be effectively leveraged to identify complex patterns associated with tumor growth, infiltration, and response to therapy.

One of the most important implications of these results is the shift from qualitative to quantitative imaging analysis in neuro-oncology. Traditional imaging interpretation relies heavily on visual assessment, which is inherently subjective and limited in its ability to capture subtle variations within tumor tissue. Radiomics, in contrast, provides objective and reproducible measurements that reflect underlying biological processes. This transition toward quantitative imaging not only improves diagnostic accuracy but also enhances the consistency of clinical assessments.

The superior performance of multimodal imaging models further emphasizes the importance of integrating diverse data sources. Gliomas are highly heterogeneous tumors, characterized by variations in cellular density, vascularity, and metabolic activity. Structural MRI provides anatomical information, while advanced imaging techniques such as diffusion and perfusion imaging offer insights into functional and microstructural properties. The combination of these modalities allows machine learning models to capture multiple dimensions of tumor biology, resulting in more accurate and reliable predictions.

Another key finding is the critical role of feature selection in optimizing model performance. The high dimensionality of radiomic data presents both an opportunity and a challenge. While a large number of features can capture detailed tumor characteristics, it also increases the risk of overfitting and reduces

model generalizability. The application of feature selection techniques, such as LASSO and principal component analysis, is therefore essential for identifying the most relevant features and improving model robustness. This highlights the importance of methodological rigor in the development of radiomics-based predictive models.

The comparison between classical machine learning and deep learning approaches provides valuable insights into their respective strengths and limitations. Deep learning models, particularly convolutional neural networks, demonstrate superior performance in handling complex imaging data and automatically extracting features. However, these models require large datasets and substantial computational resources, which may limit their applicability in certain clinical settings. Classical machine learning models, on the other hand, offer greater interpretability and may be more suitable for smaller datasets. The choice of model should therefore be guided by the specific clinical context and available resources.

From a clinical perspective, the ability to accurately predict glioma progression has significant implications for patient management. Early identification of high-risk patients allows for more aggressive treatment strategies, while low-risk patients may benefit from less intensive approaches, reducing treatment-related morbidity. Radiomics-based models also have the potential to distinguish between true tumor progression and treatment-related changes, such as pseudoprogression, which is a major challenge in neuro-oncology. This capability can improve treatment planning and reduce unnecessary interventions.

Despite these promising findings, several challenges must be addressed to facilitate the translation of radiomics and machine learning into routine clinical practice. One of the primary limitations is the lack of standardization in imaging protocols and radiomic feature extraction. Variability in image acquisition

parameters can significantly affect feature reproducibility, limiting the generalizability of predictive models. Establishing standardized imaging and analysis protocols is therefore essential for ensuring consistency across studies and clinical settings.

Another important challenge is the interpretability of machine learning models. While radiomics provides quantitative features, the relationship between these features and underlying biological processes is not always clear. Clinicians require models that not only provide accurate predictions but also offer insights into the factors driving those predictions. The integration of explainable AI techniques is therefore critical for enhancing model transparency and clinical acceptance.

Data availability and quality also represent significant barriers. Many studies are based on relatively small, single-center datasets, which may not adequately represent the diversity of patient populations. This limitation underscores the need for large-scale, multi-center studies and the development of shared databases to improve model robustness and generalizability.

Ethical and regulatory considerations further complicate the implementation of these technologies. Issues related to data privacy, algorithmic bias, and accountability must be carefully addressed to ensure the safe and responsible use of AI in healthcare. The development of clear regulatory frameworks and guidelines is essential for facilitating clinical adoption.

From a translational standpoint, the integration of radiomics-based predictive models into clinical workflows requires close collaboration between clinicians, data scientists, and engineers. User-friendly interfaces, real-time processing capabilities, and seamless integration with existing imaging systems are critical for successful implementation. Additionally, clinician training and acceptance play a key role in the adoption of these technologies.

In conclusion, the integration of radiomics and machine learning offers a powerful approach for predicting glioma progression, providing improved accuracy, enhanced understanding of tumor biology, and significant potential for clinical application. While challenges remain, continued advancements in computational methods, data standardization, and interdisciplinary collaboration are likely to drive the successful translation of these technologies into clinical practice, ultimately improving patient outcomes in neuro-oncology.

## Conclusion

The present study demonstrates that the integration of radiomics and machine learning constitutes a transformative advancement in the prediction of glioma progression, offering a shift from conventional qualitative imaging toward quantitative, data-driven precision neuro-oncology. By extracting high-dimensional imaging features and leveraging advanced computational models, radiomics-based approaches enable a more comprehensive characterization of tumor heterogeneity, which is a fundamental determinant of glioma behavior and therapeutic response.

A key contribution of this work lies in the demonstration that radiomics, when combined with machine learning, significantly enhances predictive accuracy and supports refined risk stratification. The ability to detect subtle imaging patterns associated with tumor growth, infiltration, and treatment response allows for earlier identification of disease progression, which is critical for optimizing therapeutic strategies. This is particularly important in high-grade gliomas, where rapid progression and poor prognosis necessitate timely and accurate clinical decision-making.

Furthermore, the integration of multimodal imaging data, including structural and functional MRI, represents a major step toward the realization of precision

medicine in neuro-oncology. By incorporating diverse data sources, predictive models can capture multiple dimensions of tumor biology, enabling individualized patient assessment and personalized treatment planning. This approach not only improves clinical outcomes but also reduces unnecessary interventions by enabling more targeted therapeutic strategies.

The findings also highlight the potential of radiomics-based models to improve clinical decision-making by providing objective, reproducible, and standardized assessments. These models reduce reliance on subjective interpretation and enhance consistency across clinicians and institutions. Additionally, their ability to distinguish between true tumor progression and treatment-related changes, such as pseudoprogression, addresses one of the most significant challenges in neuro-oncology.

Despite these promising advancements, several critical challenges must be addressed to facilitate the translation of these technologies into routine clinical practice. Variability in imaging protocols and lack of standardization in feature extraction remain significant barriers to reproducibility and generalizability. The high dimensionality of radiomic data also necessitates careful feature selection and validation to avoid overfitting and ensure model robustness.

Moreover, the interpretability of machine learning models remains a key concern. While deep learning approaches offer high predictive performance, their complexity can limit transparency and clinical trust. The integration of explainable AI techniques is therefore essential for enhancing model interpretability and facilitating clinical adoption.

Ethical and regulatory considerations further underscore the need for responsible implementation. Ensuring data privacy, minimizing algorithmic bias, and establishing clear accountability frameworks are critical for the safe and equitable use of AI-driven technologies in healthcare. Interdisciplinary collaboration




between clinicians, data scientists, and policymakers will be essential for developing standardized guidelines and ensuring successful integration.

In conclusion, the integration of radiomics and machine learning represents a powerful and promising approach for predicting glioma progression, with significant implications for improving diagnostic accuracy, enhancing risk stratification, and advancing personalized medicine. Continued research, methodological refinement, and clinical validation will be essential for realizing the full potential of these technologies and establishing them as integral components of future neuro-oncological practice.

**References**

1. Eric Topol (2019). *Deep Medicine*. Basic Books.
2. Ian Goodfellow et al. (2016). *Deep Learning*. MIT Press.
3. Kevin P. Murphy (2022). *Probabilistic Machine Learning*. MIT Press.
4. Даминов, Б. Т., & Ортикбоев, Ж. О. (2020). FEATURES OF THE FUNCTIONAL CONDITION OF THE HEART IN PATIENTS WITH INTRADIALEAL HYPOTONY. Новый день в медицине, (2), 78-81.
5. ОРТИКБОЕВ, Ж., & ШОЮНУСОВ, С. (2020). АСПЕКТЫ БРОНХИАЛЬНОЙ АСТМЫ. ББК 60 И 66, 144.
6. Khasanov, U. S., Djuraev, J. A., Vokhidov, U. N., Khujanov, S. K., Botirov, A. Z., & Shaumarov, A. Z. (2022). Результаты анализа частоты распределение полиморфизма a1188c rs3212227 в гене il 12b среди пациентов с хроническим полипозным риносинуситом. Oriental Journal of Medicine and Pharmacology, 2(1), 104-115.
7. Нормуродов, Б. К., Джураев, Д. А., Шаумаров, А. З., & Ахмедов, Д. М. (2020). Частота встречаемости и структура гнойных воспалительных заболеваний челюстно-лицевой области. Хирург, (7-8), 73-84.




8. Хасанов, У. С., Вохидов, У. Н., Джураев, Ж. А., Шаумаров, А. З., & Шарипов, С. С. (2020). Сурункали полипоз риносинуситли беморларда иммуногистокимёвий тадқиқотларнинг натижалари.
9. Normurodov, B. K., Djuraev, J. A., Shaumarov, A. Z., & Akhmedov, J. M. (2020). Prevalence and structure of purulent inflammatory diseases of the maxillofacial area. Central Asian Journal of Medicine, 2020, 116-130.
10. Djuraev, J. A., Khasanov, U. S., Nuridinovuch, V. U., & Zavkievich, S. A. (2021). Results of Frequency Analysis Distribution of Polymorphism Rs1800895 592c> A In Il10 Gene among Patients with Chronic Polypoid Rhinosinusitis. The International Tinnitus Journal, 25(2), 176-180.
11. Djuraev, J. A., Khasanov, U. S., Vokhidov, U. N., Botirov, A. J., Akhundjanov, N. A., & Ergashev, U. M. & Shaumarov, AZ (2021). Distribution of Allel Variants and Genotypes of Il4, Il10, Il12b, Tlr2 Genes in the Group of Patients with CPRS. Annals of the Romanian Society for Cell Biology, 4466-4470.
12. Ортикбоев, Ж. О., Газиева, Х. Ш., & Ортикбоева, Ш. О. (2019). Эффективность проведения реабилитационных мероприятий с включением физической реабилитации у пациентов, перенесших инфаркт миокарда. Евразийский кардиологический журнал, (S1), 59.
13. Хакимов, Д. П., Рустамов, А. А., Фахриев, Ж. А., & Сафаров, З. Ф. (2017). Структура травматических повреждений у детей, пострадавших вследствие дорожно-транспортных происшествий. Молодой ученый, (22), 422-425.
14. Агзамходжаев, Т. С., Расулова, Х. А., Шорахмедов, Ш. Ш., & Ортикбоев, Ж. О. (2020). DIAGNOSTIC ADVANTAGES OF CONTACTLESS BIOIMPEDANESOMETRY. Новый день в медицине, (2), 293-300.

15. Ортикбоев, Ж. О., Ортикбоева, Ш. О., & Олимхонова, К. Н. (2019). Клинико-лабораторные и инструментальные особенности влияния артериальной гипертонии на течение сахарного диабета. Евразийский кардиологический журнал, (S1), 124-125.

16. Jurakulovich, K. O., Ogli, O. J. O., Golibovna, K. G., & Bahromdjanovna, A. N. (2015). Peculiarities of dermatoglyphic values among the people of Uzbek population dependently on sex. European journal of biomedical and life sciences, (2), 35-38.

17. Ортикбоев, Ж. О., & Асадов, Н. З. (2025). СОВРЕМЕННЫЕ ПОДХОДЫ К ПРОФИЛАКТИКЕ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КЛИНИКО-ПАТОГЕНЕТИЧЕСКОЕ ОБОСНОВАНИЕ. ОСНОВЫ МЕДИЦИНЫ, 1(5), 45-51.

18. Атаходжаева, Г. А., Мирзалиева, А. А., & Султонов, С. С. (2020). Клинико-лабораторные особенности хронической сердечной недостаточности у больных мебаболическим синдромом. *Academic research in educational sciences*, (3), 541-550.

19. Рахимов, Ш. М., & Атаходжаева, Г. А. (2009). Реакция тромбоцитов на гелиогеофизические факторы у больных стабильной стенокардией в зависимости от их толерантности к физической нагрузке. *Фундаментальные исследования*, (7), 37-40.

20. Шадманова, Н. К., Рахимов, Ш. М., & Атаходжаева, Г. А. (2012). Гемодинамическая эффективность бисопролола и моксонидина и его взаимосвязь с вегетативной регуляцией у больных гипертонической болезнью при различных гелиогеофизических условиях. *Врач-аспирант*, *53*(4.2), 317-327.

21. Атаходжаева, Г. А., & Баратова, Д. С. (2017). Состояние качества жизни и толерантности к физической нагрузке больных с хронической

сердечной недостаточностью II-III функционального класса при применении антагонистов минералокортикоидных рецепторов. *Молодой ученый*, (4), 235-239.

22. Atakhodjaeva, G. A., Rakhimov, S. M., & Azimova, N. Z. (2017). Вариабельность ритма сердца у больных с хронической сердечной недостаточностью и метаболическим синдромом. *Likars' ka sprava*, (3-4), 31-37.

23. Атаходжаева, Г. А. (2021). Особенности функционального состояния почек у больных с артериальной гипертензией и сахарным диабетом 2 типа: научное издание. *Терапевтический вестник Узбекистана: научно-практический журнал.–Ташкент: ЗАО СЕАЛ МАГ*, (1), 96-99.

24. Alyavi, A. L., Rakhimova, D. A., Atakhodzhaeva, G. A., Sabirzhanova, Z. T., Gazieva, H. S., & Usmanova, U. S. (2021). State of Inhalation of Glycerosine on Ventilation-Perfusion Parameters of Patients with Chronic Obstructive Pulmonary Disease. *Annals of the Romanian Society for Cell Biology*, *25*(1), 707-711.

25. Атаходжаева, Г. А., Турсунбаев, А. К., & Собиров, Х. Г. (2017). Состояние центральной и внутрисердечной гемодинамики при остром коронарном синдроме. *Молодой ученый*, (4), 239-245.

26. Kamilova, U. M. I. D. A., Atakhodjaeva, G. U. L. C. H. E. K. H. R. A., Abdullaeva Ch, M. D., Zakirova, G., & Tagaeva, D. (2022). Features in the processes of left ventricular remodeling depending on the degree of renal dysfunction in patients with chronic heart failure. *Int J Biomed*, *12*(2), 218-21.

27. Атаходжаева, Г. А., Рахимов, Ш. М., & Азимова, Н. З. (2017). Вариабельность ритма сердца у больных с хронической сердечной недостаточностью и метаболическим синдромом. *Врачебное дело*, (3-4), 31-37.

28. Atakhodzhaeva, G. A. (2015). Rakhimov Sh. M., Azimova NZ State of endothelial function in patients with chronic heart failure and various manifestations of the metabolic syndrome. *Kardiologiya i serdechno-sosudistaya khirurgiya*, *8*(3), 76-80.
29. Ilkhamova, D., Makhkamova, M., Ortikboev, J., Makhkamova, L., & Nasimjanova, M. (2024). Diagnostics Of The Current Psychological Status Of Children With Chronic Somatic Diseases. SPAST Reports, 1(1).
30. Ортикбоев, Ж. О. (2020). ЭТИОПАТОГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ РАЗВИТИЯ СИНДИАЛИЗНОЙ ГИПОТОНИИ У БОЛЬНЫХ, ПОЛУЧАЮЩИХ ГЕМОДИАЛИЗ. Новый день в медицине, (4), 78-84.
31. Aurélien Géron (2022). *Hands-On Machine Learning*. O'Reilly.
32. Christoph Molnar (2022). *Interpretable Machine Learning*.
33. Peter Norvig & Stuart Russell (2021). *Artificial Intelligence: A Modern Approach*. Pearson.
34. Mark S. Greenberg (2020). *Handbook of Neurosurgery*.
35. Edward R. Laws Jr. (2018). *Brain Tumors*.
36. Allan H. Ropper (2019). *Principles of Neurology*.
37. Eric R. Kandel (2021). *Principles of Neural Science*.
38. Dale Purves (2018). *Neuroscience*.
39. Kaplan & Sadock (2021). *Comprehensive Textbook of Psychiatry*.
40. Judea Pearl (2018). *The Book of Why*.
41. Daniel Kahneman (2011). *Thinking, Fast and Slow*.
42. Michael Wooldridge (2021). *A Brief History of AI*.
43. Ethem Alpaydin (2021). *Machine Learning*. MIT Press.
44. Trevor Hastie (2017). *Statistical Learning*. Springer.
45. Christopher Bishop (2006). *Pattern Recognition and ML*.

46. Sebastian Raschka (2019). *Python Machine Learning*.
47. David J. Hand (2020). *The Improbability Principle*.
48. Gerd Gigerenzer (2018). *Risk Savvy*.
49. Paul Cerrato (2020). *Mobile Medicine*.
50. Oxford Editors (2019). *Oxford Handbook of Clinical Neuroscience*.
51. T.H. Jones (2018). *Clinical Neurology*.
52. Setti S. Rengachary (2019). *Principles of Neurosurgery*.
53. Joseph LeDoux (2020). *The Deep History of Ourselves*.
54. Patricia Churchland (2019). *Braintrust*.
55. Cass R. Sunstein (2020). *Too Much Information*.
56. Thomas M. Mitchell (2017). *Machine Learning*.
57. Andrew Ng (2022). *Machine Learning Yearning*.